Hepatitus B virus reactivation in HBV-DNA negative and positive patients with hematological malignancies
- 1 August 2010
- journal article
- research article
- Published by Taylor & Francis Ltd in Hematology
- Vol. 15 (4), 240-244
- https://doi.org/10.1179/102453309x12583347114059
Abstract
Reactivation of hepatitis B virus (HBV) is a frequent complication of chemotherapy (CT) in patients with HBsAg carriers. In this prospective study, we documented CT induced HBV reactivation risk in patients with hematological malignancies. HBV reactivation risk is influenced by baseline viral load. Therefore, we divided our study population into two groups according to HBV-DNA status. HBV-DNA negative patients (n=18) were treated with nucleoside analogues once HBV reactivation was observed. HBV-DNA positive patients (n=12) commenced lamivudine before the initiation of the CT. In HBV-DNA negative patients HBV reactivation was found in 10 patients (55.5%). HBV reactivation was significantly more frequent in chronic lymphocytic leukemia (CLL) patients (P=0.008) and in patients receiving rituximab containing chemotherapy regimens (P=0.06). Eight patients (80.0%) responded to antiviral treatment after HBV reactivation. Two CLL patients experienced a flare-up after the withdrawal of antiviral therapy. In HBV-DNA positive patients, HBV reactivation was observed in four patients (33.3%) during lamivudine treatment and in two patients after lamivudine withdrawal. This study demonstrated the increased risk of CT-induced HBV reactivation in CLL patients, for the first time.Keywords
This publication has 30 references indexed in Scilit:
- Hepatitis B virus reactivation following immunosuppressive therapy: guidelines for prevention and managementInternal Medicine Journal, 2007
- Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignanciesBritish Journal of Haematology, 2007
- Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapyHepatology, 2006
- A prospective study on chemotherapy-induced hepatitis B virus reactivation in chronic HBs Ag carriers with hematologic malignancies and pre-emptive therapy with nucleoside analoguesLeukemia & Lymphoma, 2006
- Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapyGut, 2005
- Prevalence of hepatitis B and C virus infection in haematological malignancies and liver injury following chemotherapyEuropean Journal of Haematology, 2005
- Lamivudine for the Prevention of Hepatitis B Virus Reactivation in Hepatitis B s-Antigen Seropositive Cancer Patients Undergoing Cytotoxic ChemotherapyJournal of Clinical Oncology, 2004
- Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphomaHepatology, 2003
- Hepatitis B Virus Infection and B‐Cell Non‐Hodgkin's Lymphoma in a Hepatitis B Endemic Area: A Case‐control StudyJapanese Journal of Cancer Research, 2002
- Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapyGastroenterology, 1991